Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025

Taysha Gene Therapies, Inc.

2025-Q2 EPS reported -$0.17 revenue$4,288,000

Cash $312.8M after $230M follow-on offering; runway extended into 2028.
Net loss $26.9M ($0.09/share) vs $20.9M ($0.09) in Q2 2024.
REVEAL pivotal trial site activation commenced; FDA and Health Canada feedback received.
100% response rate on primary endpoint in Part A; no treatment-related SAEs or DLTs in 12 patients.
New supplemental clinical data from Part A expected in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.